BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that Liberate Bio, a Boston-based biotech unleashing the potential of genetic medicines with novel delivery vehicles, has integrated the Platinum® Next-Generation Protein Sequencer™ (“NGPS”) into their platform for developing novel gene therapies with improved targeting capabilities.

康涅狄格州布兰福德——（商业新闻短讯）——Quantum Si Incorporated（纳斯达克：QSI）（“Quantum Si”，“QSI”或“公司”），蛋白质测序公司™今天宣布，总部位于波士顿的生物技术Release Bio利用新型运载工具释放基因药物的潜力，已将Platinum®下一代蛋白质测序仪™（“NGPS”）集成到其平台中，用于开发具有改进靶向能力的新型基因疗法。

Liberate is using the sequencer’s protein barcoding application to screen lipid nanoparticle delivery vehicles in vivo, with a simple readout of delivery and translation efficiency, dramatically increasing the precision, speed, and efficiency of their gene therapy discovery and development efforts..

Release正在使用测序仪的蛋白质条形码应用程序在体内筛选脂质纳米颗粒递送载体，简单地读取递送和翻译效率，大大提高了其基因治疗发现和开发工作的精度，速度和效率。。

Platinum enables advanced insights into the proteome, providing characterization of protein sequence and variation, at single-amino acid resolution. Quantum-Si’s protein barcoding application allows researchers to simultaneously tag, track, select, and measure a set of target proteins, with both in vitro and in vivo screening applications.

铂能够以单个氨基酸的分辨率深入了解蛋白质组，提供蛋白质序列和变异的表征。Quantum Si的蛋白质条形码应用程序允许研究人员通过体外和体内筛选应用程序同时标记，跟踪，选择和测量一组目标蛋白质。

And unlike alternative approaches such as mass spectrometry, it does not require expensive equipment or specialized expertise..

与质谱法等替代方法不同，它不需要昂贵的设备或专业知识。。

The integration of Quantum-Si’s barcoding application into Liberate’s platform has already shown transformative potential.

。

“The integration of Platinum’s barcoding application into our workflow represents a significant step forward, allowing us to accelerate our discovery and screening efforts with reduced costs and shortened timelines. This innovation is helping us to push the boundaries of what is possible in the development of targeted genetic therapeutics,” said Walter Strapps, Ph.D., Chief Scientific Officer of Liberate Bio..

Liberate Bio首席科学官Walter Strapps博士说：“将Platinum的条形码应用程序集成到我们的工作流程中是向前迈出的重要一步，这使我们能够以更低的成本和更短的时间表加速我们的发现和筛选工作。这一创新有助于我们突破靶向基因治疗开发的可能界限。”。。

Liberate’s work with Platinum underscores the transformative impact that NGPS can have on the pharmaceutical and biotech industry, particularly in gene therapy and drug discovery. “Platinum’s barcoding application is revolutionizing the way researchers approach drug discovery and development. Liberate’s work exemplifies how this technology can unlock new possibilities in drug discovery, driving progress in the field,” said Jeff Hawkins, Chief Executive Officer of Quantum-Si..

Liberate与铂的合作突显了NGP对制药和生物技术行业的变革性影响，特别是在基因治疗和药物发现方面。Quantum Si首席执行官杰夫·霍金斯（Jeff Hawkins）表示：“铂的条形码应用正在彻底改变研究人员进行药物发现和开发的方式。解放的工作证明了这项技术如何开启药物发现的新可能性，推动该领域的进步。”。。

About Liberate Bio

关于解放生物

Liberate Bio is a leading biotechnology company focused on revolutionizing drug discovery and development. With a commitment to innovation and precision, Liberate Bio utilizes advanced technologies to develop targeted therapeutics that address unmet medical needs. For more information, visit https://www.liberatebio.com/..

解放生物是一家领先的生物技术公司，专注于彻底改变药物的发现和开发。Liberate Bio致力于创新和精准，利用先进技术开发针对未满足医疗需求的靶向治疗方法。有关更多信息，请访问https://www.liberatebio.com/..

About Quantum-Si Incorporated

关于Quantum Si Incorporated

Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing.

蛋白质测序公司Quantum Si专注于彻底改变蛋白质组学的发展领域。该公司的一套技术由同类半导体芯片提供动力，该芯片旨在实现下一代单分子蛋白质测序和蛋白质组学研究数字化，以推动药物发现和诊断超越DNA测序的可能性。

Learn more at quantum-si.com or follow us on LinkedIn or X..

。。

Forward Looking Statements

前瞻性声明

This press release includes 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events.

本新闻稿包括1995年《美国私人证券诉讼改革法案》中“安全港”条款所指的“前瞻性声明”。公司的实际结果可能与其预期、估计和预测不同，因此，您不应将这些前瞻性陈述视为对未来事件的预测。

Words such as 'expect,' 'estimate,' 'project,' 'budget,' 'forecast,' 'anticipate,' 'intend,' 'plan,' 'may,' 'will,' 'could,' 'should,' 'believes,' 'predicts,' 'potential,' 'continue,' and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements.

诸如“期望”、“估计”、“项目”、“预算”、“预测”、“预期”、“打算”、“计划”、“可能”、“意志”、“可能”、“应该”、“相信”、“预测”、“潜力”、“继续”等词语以及类似的表达（或此类词语或表达的负面版本）旨在识别此类前瞻性陈述。

These forward-looking statements include, without limitation, the Company's expectations with respect to future performance and development and commercialization of products and services. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements.

这些前瞻性陈述包括但不限于公司对未来业绩以及产品和服务的开发和商业化的期望。这些前瞻性陈述涉及重大风险和不确定性，可能导致实际结果与前瞻性陈述中讨论的结果存在重大差异。

Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company's Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company’s ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product development and commercialization activities; the commercialization and adoption of the Company’s existing products and the success of any product the Compan.

这些因素大多不在公司的控制范围内，很难预测。；公司盈利增长和管理增长并留住关键员工的能力；公司正在进行的领导层过渡；适用法律法规的变更；公司未来融资的能力；公司产品开发和商业化活动的成功率、成本和时间安排；公司现有产品的商业化和采用以及公司任何产品的成功。